{"pub": "axios", "url": "https://wsj.com/articles/fda-committee-recommends-withdrawing-treatment-to-prevent-preterm-births-from-market-11572387799?mod=lead_feature_below_a_pos1", "downloaded_at": "2019-10-30 10:48:45.107904+00:00", "title": "FDA Committee Recommends Withdrawing Treatment to Prevent Preterm Births From Market", "language": "en", "text": "A U.S. Food and Drug Administration advisory committee recommended Tuesday that the standard treatment to prevent women from having another preterm birth, Makena, be withdrawn from the market in a 9-to-7 vote following a public hearing.\n\nThe FDA approved the treatment, now made by AMAG Pharmaceuticals Inc., in 2011, contingent upon completing a follow-up study. That study, published last week in the American Journal of Perinatology, found that the weekly synthetic progestin injections didn\u2019t decrease recurrent preterm births...", "description": "A U.S. Food and Drug Administration advisory committee recommended that the standard treatment to prevent women from having another preterm birth, Makena, be withdrawn from the market in a 9-to-7 vote.", "authors": ["Sumathi Reddy", "Sumathi.Reddy Wsj.Com"], "top_image": "https://images.wsj.net/im-121877/social", "published_at": "2019-10-29"}